Healthcare (SH:603313)2021-10-29 16:00Financial Performance - The company's revenue for Q3 2021 was ¥2,210,469,039.75, representing a year-over-year increase of 4.75%[5] - The net profit attributable to shareholders for Q3 2021 was -¥188,925,955.63, a decrease of 199.03% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2021 was -¥26,632,846.55, down 115.25% year-over-year[5] - Total operating revenue for Q3 2021 reached ¥6,110,467,573.29, a 35.1% increase from ¥4,526,354,598.57 in Q3 2020[36] - Net profit for Q3 2021 was a loss of ¥162,568,503.97, compared to a profit of ¥374,518,147.83 in Q3 2020[39] - The total comprehensive income for the period was -251,036,809.17 RMB, compared to 364,903,793.09 RMB in the previous period[41] - Basic earnings per share were -0.45 RMB, down from 1.01 RMB in the same period last year[41] Cash Flow and Liquidity - The net cash flow from operating activities for Q3 2021 was -¥153,027,437.54, a decline of 164.78% compared to the previous year[7] - Net cash flow from operating activities was -337,912,158.90 RMB, a significant decrease from 586,194,583.52 RMB in the previous year[45] - Cash inflow from operating activities totaled 6,411,358,104.30 RMB, compared to 4,726,534,032.63 RMB in the prior year[45] - Cash outflow from operating activities was 6,749,270,263.20 RMB, up from 4,140,339,449.11 RMB in the previous year[46] - The ending balance of cash and cash equivalents was 530,418,643.87 RMB, compared to 1,003,618,901.38 RMB at the end of the previous period[46] - The company's cash and cash equivalents decreased to RMB 562,309,335.55 from RMB 1,070,561,346.05, a decline of approximately 47.5%[27] Assets and Liabilities - The total assets at the end of Q3 2021 were ¥8,599,226,831.60, an increase of 21.53% from the end of the previous year[8] - The company's total liabilities increased to ¥5,315,957,172.40 in Q3 2021 from ¥3,382,596,960.38 in Q3 2020, reflecting a 57.4% rise[36] - The total equity attributable to shareholders decreased to ¥3,166,769,838.53 in Q3 2021 from ¥3,556,693,841.04 in Q3 2020, a decline of 11%[36] - The total liabilities and equity combined reached CNY 7.08 billion, showing a comprehensive financial position[59] - Total current assets amounted to approximately CNY 3.85 billion, showing a decrease of CNY 1.8 million compared to the previous period[52] Shareholder Information - The company has a total of 26,666 common shareholders at the end of the reporting period, with the largest shareholder holding 49.27% of the shares[17] - The company has a significant shareholder structure, with the top ten shareholders holding a total of 239,721,715 shares, representing a substantial portion of the equity[21] Operational Costs and Expenses - The company faced significant increases in raw material and labor costs, impacting cash flow and profitability[15] - Total operating costs for Q3 2021 were ¥6,087,652,851.56, up 50.7% from ¥4,043,006,197.76 in Q3 2020[36] - Research and development expenses for Q3 2021 were ¥93,957,318.57, an increase of 18.5% from ¥79,090,676.14 in Q3 2020[36] - The company reported a significant increase in sales expenses, totaling ¥917,094,139.67 in Q3 2021, compared to ¥842,949,377.88 in Q3 2020, indicating higher marketing efforts[36] Inventory and Receivables - Accounts receivable increased to RMB 1,320,099,617.79 from RMB 997,203,325.96, reflecting a growth of approximately 32.4%[30] - Inventory levels rose to RMB 1,853,428,186.12, compared to RMB 1,367,748,411.47, indicating a significant increase of about 35.5%[30] - The company reported a provision for bad debts of RMB 1,232,079.56 related to accounts receivable from a lawsuit, impacting profits by approximately RMB 160 million[26] Legal and Regulatory Matters - The company is involved in ongoing litigation that may affect its financial position, with a potential liability of USD 25.93 million[26]